Good MorningDespite some volatility, the Santa Claus Rally appears to be on track to lift the market into year-end. The S&P 500 extended its holiday-week rebound on Wednesday putting the index within an arm’s reach of the current all-time high. The question that needs to be asked, though, is what will the New Year bring?
The only certainty for the New Year is inflation. Inflation is running rampant through the economy and threatens to dampen consumption on many levels. The caveat for investors is that, until the market gives the signal for reversal, the trend in the market is up. If the S&P 500 can break out to a new high, we see it continuing upward at least until the Q4 earnings cycle gets underway.
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Technology | |
Recent upgrades make a strong case for AAPL stock to move past its 52-week high
After not doing much of anything for most of the year, Apple (NASDAQ:AAPL) stock has made a strong move in the last two months of the year. As recently as October 13, 2021, AAPL stock was a market laggard being up ju... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Consumer Discretionary | |
Insider Selling In Carmax Ceases In Q4
Insiders were selling Carmax (NYSE: KMX) earlier this year but that activity has stopped. Insiders sold 925,010 shares during the first three quarters of the year but there has been no activity of record in the time since. The selling equals 0.57% of the sh... Read the Full Story |
|
Technology | |
Customer relation management (CRM) software company Salesforce.com (NYSE: CRM) stock has been plunging on its latest top and bottom-line guidance stemming from the fiscal Q3 2022 earnings call. While the fiscal Q3 2021 earnings were very strong, the lowered guidance shocked investors. Arguably, Sa... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Consumer Discretionary | |
Connected home fitness equipment maker and platform Peloton (NASDAQ: PTON) stock has been a nasty rollercoaster ride for investors. The popular connected fitness company bounced off $17.70 COVID lows to peak at $171.09 before plunging on the reopening trend back into the $30s. The Company has yet ... Read the Full Story |
|
Markets | |
Going into the new year, you may wonder what you should invest in: artificial intelligence, cyclical stocks, health care? A combination of these or something else entirely?
It's a great question. Based on the unique events from last year, rising interest rates and consumer pushes toward specific... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Discretionary | |
It’s that time of year for investors. Hopes for a Santa Claus rally, some much needed R&R, and yes—tax loss harvesting.
The annual ritual of dumping the year’s losers to offset capital gains taken early in the year is far from a festive event but can be a valuable part of ta... Read the Full Story |
|
Markets | |
Analysts are taking a more favorable view of T stock as the TimeWarner nears completion
AT&T (NYSE:T) stock is enjoying its best week since early summer. T stock is up 6.5% since December 16. The reason for the optimism is stemming from two analysts' upgrades. In both cases, the stock was up... Read the Full Story |
|
Consumer Discretionary | | It wouldn’t be like Tesla (NASDAQ: TSLA) to keep their investors guessing would it? After rallying more than 100% from July through the start of November, the brakes were firmly applied when CEO Elon Musk announced his intention to start unloading huge portions of his stock holdings to meet hi... Read the Full Story |
|
Industrials | |
Insiders Have Skin In Paychex, Inc
Yes, the insiders have been selling some shares of Paychex, Inc (NASDAQ: PAYX) this year but it is nothing for investors to be worried about. If anything, insiders should have waited longer to do their selling, and, ultimately, their activity speaks volumes. Wh... Read the Full Story |
|
Industrials | |
Cintas Beats And Raises Guidance, Preps For Growth
Cintas (NASDAQ: CTAS) is not immune to the impacts of inflation and supply chain issues but those issues are symptoms of an otherwise strong economy. An economy that is creating new jobs at a record pace, has employment at record levels and driv... Read the Full Story |
|
The Early Bird Stock Of The Day Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. | | View Today's Stock Pick |
|
